HCC: Epidemiology. Update on treatment of advanced hepatocellular carcinoma. Incidence of HCC is increasing
|
|
- Abraham Gardner
- 5 years ago
- Views:
Transcription
1 Update on treatment of advanced hepatocellular carcinoma Jean-Luc Raoul Centre E Marquis Rennes, Brittany France HCC: Epidemiology Europe - USA: C virus, alcohol obesity, iron Europe: 4 deaths / year 6 - M cases / year Asia: 4 deaths / year Asia Africa: B virus, aflatoxin Bosch FX et al Gastroenterology 24 Incidence of HCC is increasing In most western countries : st cause of death among cirrhotic = HCC, New etiologies: HCV induced HCC will peak in 25 NASH: Obesity, diabetes, Immigration. But also in some high incidence countries
2 BCLC staging system: linking staging to treatment (BCLC) 5-year overall survival = 4 à 7% Median overall survival 6 à 6 months Survival < 3 months Treatment of advanced HCC Progress OLT, down-staging and advanced HCC Radiological techniques Intra-arterial Percutaneous 2 Systemic treatments Hormone therapies Chemotherapies Targeted treatments Liver Transplantation, down-staging and advanced HCC 2
3 Down staging prior to LT () Prospective study of patients with tumour stage >T2 (22 7) Eligibility for down staging LN: 5 8cm 2 3 LN: one >3cm, all <5cm, total <8cm 4 5 LN: none >3cm, total <8cm Transplantation if UCSF criteria met LN: <6.5cm 2 3 LN: none >4.5cm, total <8cm Follow-up period >3 months after down staging Down-staging treatments (n=6) TACE (n=5) RFA (n=) TACE + RFA/percutaneous ablation (n=29) resection (n=6) Yao FY et al, Hepatology 28 Down staging prior to LT (2) Down staging to within conventional criteria can be achieve in the majority of patients with an excellent outcome Yao FY et al, Hepatology 28 Radiological techniques 3
4 Treatment for advanced HCC: transarterial embolisation/chemoembolisation Patients with unresectable HCC Transarterial embolisation administered with/without chemotherapy (e.g. doxorubin, cisplatin) Only given to patients with well-preserved liver function (Child A) good Performance Status (PS ) no tumour-related symptoms no extrahepatic spread or vascular invasion Severe side effects common Llovet JM. J Gastroenterol 25;4: Meta-analysis: 2-year survival with TACE/embolisation versus supportive care for unresectable HCC Study Number of patients Odds ratio (95% CI) in random effects model Lin, et al GETCH Bruix, et al Pelletier, et al Lo, et al Llovet, et al 22 2 Overall 53 p= Heterogeneity p=.4 Favours treatment Favours control CI = confidence interval Modest survival benefit with TACE/embolisation (median OS: 6 to 2 mo) Not a standardized treatment Llovet JM, et al. Lancet 23;362:97 7 Chemoembolization Use of reproducible treatment : DC bead: controled drug delivery system, Promising results in phase II, Phase III: PRECISION V: TACE with doxo: Pts vs DC bead + doxo: Pts Primary objective: ORR at 6 mo Lammer J, et al CIRSE 28 4
5 PRECISION V TRIAL Conclusions: In overall, DC bead has: Greater objective response rate NS:. Lower SAE & AE DC bead has a significant advantage in: ORR in more advanced patients.38 DCR in more advanced patients.26 Reduction in doxo SAE. in all patients Lammer J, et al CIRSE 28 Chemoembolization + RFTA Chemoembolization, RFTA, combination: < 3 lesions, 3 7,5 cm, Child A, 29 Pts TACE 2 weeks rest then RFA New Standard? Cheng BQ et al. JAMA 28 RFA: +/- PEI RFTA: with percutaneous ethanol injection 33 patients CHC: solitary < 7 cm 2 ou 3 nodules: < 3 cm Randomisation: RFA (n = 67) PEI then ( min) RFA (n = 66) Stratification / size (< 3, 3 5, > 5 cm) Zhang YJ et al. Radiology 27 5
6 All < 3 cm P =.4 NS P =.3 NS 3 5 cm > 5 cm New Standard? 2 Systemic treatments Hormone therapies Hormone therapies anti-androgens tamoxifen somatostatin analogues No survival advantage over symptomatic treatment. Llovet JM, et al. Lancet 23;362:97 7 FFCD double blind trial: LA SMS vs placebo? Survival probabilities Number at risk Octreotide Placebo Kaplan-Meier survival estimates Time in months Barbare JC, submitted Octreotide Placebo 6
7 Systemic chemotherapies Phase II studies Single-agent therapies : doxorubicin, cisplatin, 5-FU, Pegylated liposomal doxorubicin and nolatrexed Combination regimens : PIAF 2 XELOX 3 and GEMOX 4 objective response rates < 2 25 % substantial toxicity reported (e.g. HBV re-activation) 5 Conclusion: «promising, manageable toxicity». Nowak AK, et al. Eur J Cancer Yeo W, et al. J Natl Cancer Inst Boige V, et al. Br J Cancer Louafi S, et al. Cancer Yeo W, et al. Ann Oncol 24 Systemic chemotherapy for advanced HCC Phase III studies: PIAF Variable Doxorubicin n=94 PIAF n=94 p value Overall response rate, % Grade 3 4 toxicities Treatment-related deaths, % 3 9 NS Median OS, months NS OS = overall survival Yeo W, et al. J Natl Cancer Inst 25 7
8 Systemic chemotherapy for advanced HCC Phase III studies: nolatrexed Variable Doxorubicin n=222 Nolatrexed n=222 p value Overall response rate, % 4..4 Grade 3 4 toxicities Median progression-free survival, weeks 2 NS Median OS, weeks Gish RG, et al. J Clin Oncol 27 Chemotherapy for unresectable HCC in non-cirrhotic liver Chemotherapy for HCC/cirrhotic liver is toxic and poorly effective Retrospective analysis of 24 patients (7 years) HCC with normal or fibrous (F, F2) liver treatments: ECC/ECF (n=2), FOLFOX (n=3), FOLFIRI (n=) toxicity sudden death grade 4 cardiac (n=), grade 3 neutropenia (n=5) efficacy 5 PR (ORR 22%) surgical resection in 2 (alive after 6 and 2 years) median OS 9 months (-/3-year survival 5/9%) Chemotherapy for HCC/non-cirrhotic liver poorly effective, but Edeline J, WJG 29 8
9 Systemic treatments Molecular pathogenesis of HCC Multiple mechanisms implicated in hepatocarcinogenesis Liver cirrhosis following tissue damage Mutations occurring in oncogene or tumor suppressor gene Cellular signaling pathways that are often dysregulated in HCC include 2 : Angiogenic signaling EGF/EGFR PI3K/Akt/mTOR Ras/Raf/MEK/ERK Key targets for molecular therapy Wnt/β-catenin P3K = phosphoinositide 3-kinase; Akt = protein kinase B; mtor = mammalian target of rapamycin; Raf = serine-threonine protein kinase (c-raf); Ras = small GTPase; MEK = mitogen-activated protein kinase; ERK = extracellular signalregulated kinase; Wnt = secreted signaling protein. Thorgeirsson S, et al. Hepatology 26; 2. Avila MA, et al. Oncogene 26. Major pathways dysregulated in HCC Villanueva A Semin Liver Dis 27 9
10 Systemic treatments Targeted therapies Multiples agents (Ph II):Single agent or in combination; : positive phase III trials Bevacizumab: mab anti VEGF Responses but side effects Erlotinib: EGFR TKI stabilizations Sunitinib: multi TKI Responses But toxicities? Brivanib: multi TKI Biological responses Good Tolerance All are entering in Phase III RCT Bevacizumab Phase II study, n = 46 ORR: 3 % PFS 6 mo = 65% Reduction in tumor enhancement Decrease in VEGF level Toxicity: SAE Hypertension (5 %), thrombosis (6%, arterial = 4%) GI bleedings ( %) Siegel AB, et al J Clin Oncol 28 Sunitinib MTKI, targets: VEGFR, PDGFR, c-kit, RET, FLT3 Sunitinib: oral HCC patients; SU 5mg/d, 4/2 schedule 37 pts, PS (5%), Child-P A (84%) Toxicities Gr 3 4: Plat 43%, PMN 24%, CNS 24%, asthenia 22%, Hemorrhage 4% 4 deaths: ascites, edema, bleeding, drowsyness, encephalopathy Efficacy: PR (3%) and 39% SD Recap: dose or schedule modification improving Pt selection Faivre SJ, et al ASCO 27 # 3546
11 Sunitinib SU: 37.5 mg/d 4/2 schedule DCE MRI to assess changes in tumor permeability 9 Pts, ECOG /: 7/2 Toxicity: PMN 2%, Lym: 6%, plat: % transa 6%, fatigue %, rash: %, Efficacy: PR, 8 SD Tumor permeability: 52% decrease Changes in angiogenic markers Zhu AX et al ASCO 27 # 4637 Brivanib Targets FGFR and VEGFR Phase II: 55 Pts ORR = 6 %, DCR = 47 % Decrease in AFP: 49 % Toxicity: fatigue, hypertension, diarrhea Park JW, ILCA mm 92 mm June, 4th, 27 AFP = Nl Initiation of Brivanib Tt
12 Nov th, 28 7 months of Brivanib 63 mm 23 mm 92 mm 65 mm Baseline June, 4th, 27 targets tumor cell proliferation and angiogenesis Tumor cell Endothelial cell or pericyte (vascular) RAS HGF Apoptosis Autocrine loop Paracrine stimulation PDGFR-β PDGF-β RAS VEGF VEGFR-2 RAF Mcl- Mitochondria MEK ERK HIF HGF PDGF VEGF Nucleus Proliferation Survival RAF Mitochondria MEK Apoptosis ERK Nucleus Angiogenesis: Differentiation Proliferation Migration Tubule formation Avila MA, et al. Oncogene 26; Liu L, et al. Cancer Res 26; Semela D, et al. J Hepatol 24; Wilhelm SM, et al. Cancer Res 24. Phase II trial of sorafenib in HCC: study design Eligibility Advanced HCC ECOG PS Child-Pugh Class A or B No prior systemic therapy N=37 4 mg bid Primary end points Tumor response (modified WHO) Safety (NCI-CTC v2.) ECOG PS = Eastern Cooperative Oncology Group Performance Status; NCI-CTC = National Cancer Institute-Common Toxicity Criteria; WHO = World Health Organization. Abou-Alfa GK, et al. J Clin Oncol 26 2
13 Phase II trial: one-third of patients with advanced HCC achieved stable disease Best response (independent assessment) n (%) [total N=37] PR 3 (2.2) MR 8 (5.8) SD ( 6 weeks) 46 (33.6) PD (by radiologic assessment) 48 (35.) Not available for independent review 32 (23.4) Median TTP, mo. Median OS, mo PR = partial response; MR = minor response; SD = stable disease; PD = progressive disease; TTP = time to tumor progression; OS = overall survival. Abou-Alfa GK, et al. J Clin Oncol 26 Phase II trial: conclusions has antitumor activity PR/MR: 8% of patients SD for 6 weeks in 34% of patients Tumor necrosis, increasing with time; Median TTP: 5.5 months (independent assessment) Median OS: 9.2 months is generally well tolerated Common AEs: diarrhea, HFSR and fatigue Safety profiles for Child-Pugh Class A and B patients were similar Abou-Alfa GK, et al. J Clin Oncol 26 Phase III SHARP Design Eligibility criteria Advanced HCC Child Pugh A status ECOG PS 2 Life expectancy 2 weeks Randomization 4mg b.i.d. n=299 Placebo n=33 Primary endpoints OS TTSP Double-blind, versus placebo; ratio : Secondary endpoints TTP tolerance Llovet J, N Engl J Med 28 3
14 Phase III SHARP Trial: Baseline Characteristics of Patients Placebo Characteristics (n=299) (n=33) Age (median, years) Male/Female (%) Region (Europe/N America/others) (%) Etiology (%) Viral Hepatitis (HCV/HBV) Alcohol/other Child Pugh (A/B; %) Prior therapies (%) Surgical resection Loco-regional therapies 65 87/3 88/9/3 29/9 26/26 95/ /3 87//3 27/8 26/29 98/2 2 4 Llovet J, N Engl J Med 28 Phase III SHARP Trial: Baseline Characteristics of Patients Placebo Characteristics (n=299) (n=33) BCLC stage 2 (%) Stage B (intermediate stage) Stage C (advanced stage) ECOG PS (%) 2 Macroscopic vascular invasion (portal vein) and/or extrahepatic spread (%) Present Absent Llovet J, N Engl J Med 28 Results 4
15 Survival probability Patients at risk : Placebo: Phase III SHARP Trial: OS (Intention-to-treat) Hazard ratio (S/P):.69 (95% CI:.55.88) p=.58* Median: 46.3 weeks (.7 months) (95% CI: ) Placebo Median: 34.4 weeks (7.9 months) (95% CI: ) 44 % 33 % Weeks Llovet J, N Engl J Med 28 Progression-free probability Phase III SHARP Trial: TTP (Independent Central Review) Median: 24. weeks (5.5 months) (95% CI: 8. 3.) Placebo Median: 2.3 weeks (2.8 months) (95% CI:.7 7.).25 Hazard ratio (S/P):.58 (95% CI:.44.74) p= Patients at risk Time (Weeks) : Placebo: Llovet J, N Engl J Med 28 Phase III SHARP Trial: Response Assessment (RECIST; Independent Review) and TTSP (FSHI8-TSP) Overall response CR PR SD PD Progression-free rate at 4 months Duration of treatment (median, weeks) (n=299) 7 (2.3%) 2 (7%) 54 (8%) 62% 23 Placebo (n=33) 2 (.7%) 24 (67%) 73 (24%) 42% 9 FSHI8-TSP: no significant differences between treatment groups (p=.77) RECIST = Response Evaluation Criteria In Solid Tumors Llovet J, N Engl J Med 28 5
16 Phase III SHARP Trial: Safety Events Treatment-emergent serious adverse events (SAE, %) Drug-related treatment-emergent SAE (%) Drug-related adverse events (%) Diarrhea Pain (abdomen) Weight loss Anorexia Nausea HFSR Vomiting Alopecia Liver dysfunction Bleeding All < 7 (n=297) 52 3 Grade 3 4 8/ 2/ 2/ </ </ 8/ / / </ </ All 3 < Placebo (n=32) 54 9 Grade 3 4 2/ </ / </ / </ </ / / </< Llovet J, N Engl J Med 28 Phase III SHARP Trial: Conclusions prolonged overall survival versus placebo in advanced HCC Median OS.7 mo versus 7.9 mo Hazard ratio:.69, p=.58 44% increase in OS prolonged TTP versus placebo Median TTP 5.5 mo vs 2.8 mo Hazard ratio:.58, p=.7 73% prolongation in TTP was well tolerated with manageable side effects Llovet J, N Engl J Med 28 SHARP Study Design Schema for Subanalyses MVI/EHS Present MVI/EHS Absent n=29 n=9 Eligibility Advanced HCC ECOG PS -2 Child-Pugh class A No prior systemic therapy Stratification MVI (portal vein) and/or EHS ECOG PS ( vs -2) Geographic region R A N D O M I Z E : Primary end points: OS, TTSP (FHSI-8) Secondary end points: TTP (independent assessment) * 4 mg bid n=299 Placebo* n=33 *Repeated 6-week cycles until both radiologic progression AND symptomatic progression criteria were met, or unacceptable toxicity or death. n=22 n=9 ECOG PS ECOG PS - 2 n=6 n=38 n=64 n=39 Raoul JL, ILC 28 6
17 Overall Survival by MVI and/or EHS MVI/EHS Present MVI/EHS Absent. (n=29) Median: 8.9 mo 95% CI: (n=9) Median: 4.5 mo 95% CI: 4.-N/E Survival Probability Placebo (n=22) Median: 6.7 mo 95% CI: Survival Probability Placebo (n=9) Median:.2 mo 95% CI: HR (95% CI):.77 (.6-.99) Months HR (95% CI):.52 ( ) Months TTP by MVI and/or EHS (Independent Assessment) MVI/EHS Present MVI/EHS Absent. (n=29) Median: 4. mo 95% CI: (n=9) Median: 9.6 mo 95% CI: 6.9-N/E Progression-Free Probability Placebo (n=22) Median: 2.7 mo 95% CI: Progression-Free Probability Placebo (n=9) Median: 4.3 mo 95% CI: HR (95% CI):.64 ( ) Months HR (95% CI):.4 (.23-.7) Months Overall Survival by ECOG PS ECOG PS ECOG PS -2. (n=6) Median: 3.3 mo 95% CI: 9.9-N/E. (n=38) Median: 8.9 mo 95% CI: Survival Probability Placebo (n=64) Median: 8.8 mo 95% CI: Survival Probability Placebo (n=39) Median: 5.6 mo 95% CI: HR (95% CI):.68 (.5-.95) Months HR (95% CI):.7 ( ) Months 7
18 TTP and TTSP by ECOG PS Favors Favors Placebo TTP ECOG PS ECOG PS -2 TTSP ECOG PS ECOG PS Hazard Ratio Conclusions is the first systemic treatment to demonstrate efficacy in patients with advanced HCC is the only systemic therapy approved by the FDA and EMEA for the treatment of patients with HCC prolonged survival in HCC patients, regardless of their MVI/EHS or ECOG PS status, thereby confirming the effectiveness of sorafenib in a broad range of patients was well tolerated, regardless of ECOG PS status or MVI/EHS presence at baseline in HCC patients from the Asia Pacific Region 8
19 Asia-Pacific study: Design Eligibility Advanced HCC ECOG PS 2 Child-Pugh Class A No prior systemic therapy Stratification Macroscopic vascular invasion (portal vein) and/or extrahepatic spread ECOG PS ( vs 2) Geographic region R A N D O M I Z E 2: n=5 n=76 4 mg bid Placebo End points: Overall survival, time to symptomatic progression (FSHI8-TSP), time to progression, response (RECIST), and safety No primary end point defined Cheng A, et al. J Clin Oncol 28;26: abstract 459. Adapted from poster presented at ASCO Annual Meeting; May 3-June 3, 28; Chicago, IL. Asia-Pacific study: Baseline patient characteristics Median age (range), y Male, % ECOG PS, % 2 Macroscopic vascular invasion, % No Yes Extrahepatic spread, % No Yes BCLC Stage C, % (n=5) 5 (23 86) Placebo (n=76) 52 (25 79) Cheng A, et al. J Clin Oncol 28;26: abstract 459; Adapted from poster presented at ASCO Annual Meeting; May 3-June 3, 28; Chicago, IL. Asia-Pacific study: Baseline patient characteristics No. of tumor sites, % Sites of disease, % Lung Lymph node Hepatitis virus status, % HBV HCV Child-Pugh Class A, % Liver cirrhosis (clinical), % AFP > ULN (laboratory), % (n=5) Placebo (n=76) Cheng A, et al. J Clin Oncol 28;26: abstract 459; Adapted from poster presented at ASCO Annual Meeting; May 3-June 3, 28; Chicago, IL. 9
20 Survival probability Patients at risk Placebo Asia-Pacific study: Overall survival.25 HR S/P:.68 95% CI:.5,.93 p= Months (n=5) Median OS: 6.5 mo. 95% CI: 5.6, 7.6 Placebo (n=76) Median OS: 4.2 mo. 95% CI: 3.7, 5.5 Cheng A, et al. J Clin Oncol 28;26: abstract 459; Adapted from poster presented at ASCO Annual Meeting; May 3-June 3, 28; Chicago, IL Survival probability Asia-Pacific study: Time to progression HR S/P:.57 95% CI:.42,.79 P<. (n=5) Median TTP: 2.8 mo. 95% CI: 2.6, 3.6 Placebo (n=76) Median TTP:.4 mo. 95% CI:.3,.5 Patients at risk 5 Placebo Months Cheng A, et al. J Clin Oncol 28;26: abstract 459; Adapted from poster presented at ASCO Annual Meeting; May 3-June 3, 28; Chicago, IL. Asia-Pacific study: Response by RECIST ORR (CR+PR), % CR PR SD, % PD, % DCR*, % (n=5) Placebo (n=76) *Independent review by Response Evaluation Criteria in Solid Tumors (RECIST). DCR = complete response (CR) + partial response (PR) maintained for 4 weeks + stable disease (SD) documented at least 2 weeks from baseline. Cheng A, et al. J Clin Oncol 28;26: abstract 459; Adapted from poster presented at ASCO Annual Meeting; May 3-June 3, 28; Chicago, IL. 2
21 Asia-Pacific study: Adverse events occurring in % of patients Treatment-related SAEs, % Drug-related SAEs, % Drug-related AEs*, % Hand-foot skin reaction Diarrhea Alopecia Fatigue Rash/desquamation Hypertension Anorexia Nausea (n=49) 48 9 Any / Grade Placebo (n=75) 45 Any / 4 Cheng A, et al. J Clin Oncol 28;26: abstract 459; Adapted from poster presented at ASCO Annual Meeting; May 3-June 3, 28; Chicago, IL. Asia-Pacific study: Subset analyses Favors sorafenib Favors placebo Age 65 Yes (n=32) No (n=94) Macroscopic vascular invasion (MVI) Yes (n=8) No (n=46) Extrahepatic spread (EHS) Yes (n=55) No (n=7) MVI and/or EHS Yes (n=79) No (n=47) ECOG PS (n=59) /2 (n=67) Hazard ratio for OS Cheng A, et al. J Clin Oncol 28;26: abstract 459; Adapted from poster presented at ASCO Annual Meeting; May 3-June 3, 28; Chicago, IL. Conclusions significantly prolonged OS over placebo in advanced HCC Median OS: 6.5 vs 4.2 months Hazard ratio:.68, P=.4 47% increase in OS prolonged TTP over placebo Median TTP: 2.8 vs.4 months Hazard ratio:.57, P<. 74% prolongation in TTP was well tolerated and had manageable side effects is effective in patients with HCC from the Asia-Pacific region 2
22 in combination with doxorubicin in HCC Phase II trial of doxorubicin ± sorafenib in HCC: study design Period Period 2* Eligibility Advanced HCC ECOG PS -2 Child-Pugh Class A No prior systemic therapy No prior chemoembolization No history of organ allograft R A N D O M I Z E n = 47 n = 49 : Primary objective TTP (independent assessment) Secondary objectives ORR, PFS, OS, safety Doxorubicin 6 mg/m 2 + sorafenib 4 mg bid q3w Doxorubicin 6 mg/m 2 + placebo q3w 4 mg bid Placebo * or placebo continued until withdrawal, PD, or death in period 2. q3w = once every three weeks; TTP = time to progression; ORR = overall response rate; PFS = progression-free survival; OS = overall survival Abou-Alfa GK, et al. Eur J Cancer Suppl. 27;5(4):259; updated from abstract 28. Poster and oral presentation at ASCO-GI; Orlando, FL; January 28. Phase II trial of doxorubicin ± sorafenib in HCC: TTP (independent assessment). Doxorubicin + sorafenib Median: 8.6 months (95% CI: 4.8, 2.6) Progression-free probability HR D+S/D+P =.6 p =.76 Doxorubicin + placebo Median: 4.8 months (95% CI: 2.2, 8.) Censored treatment Months Abou-Alfa GK, et al. Eur J Cancer Suppl. 27;5(4):259; updated from abstract 28. Poster and oral presentation at ASCO-GI; Orlando, FL; January
23 Phase II trial of doxorubicin ± sorafenib in HCC: OS Survival probability HR D+S/D+P =.45 p =.5 Doxorubicin + sorafenib Median: 3.7 months (95% Cl:.4 NA) Doxorubicin + placebo Median: 6.5 months (95% Cl: ) Months from randomisation Definitive analysis (data from March 27 cut-off, 5 events). NA = value can not be estimated due to censored data. Abou-Alfa GK, et al. Eur J Cancer Suppl. 27;5(4):259; updated from abstract 28. Poster and oral presentation at ASCO-GI; Orlando, FL; January 28. Phase II trial of doxorubicin ± sorafenib in HCC: AEs with % grade 3/4 incidence Fatigue Neutropenia Diarrhea Elevated bilirubin Abdominal pain HFSR Left ventricular dysfunction Hypertension Febrile neutropenia Doxorubicin + sorafenib (n = 47) Any grade Grades 3/ Doxorubicin + placebo (n = 49) Any grade Grades 3/ Abou-Alfa GK, et al. Eur J Cancer Suppl. 27;5(4):259; updated from abstract 28. Poster and oral presentation at ASCO-GI; Orlando, FL; January 28. Phase II trial of doxorubicin ± sorafenib in HCC: conclusion has shown promising efficacy and tolerability when combined with doxorubicin in the phase II setting in patients with advanced HCC Abou-Alfa GK, et al. Eur J Cancer Suppl. 27;5(4):259; updated from abstract 28. Poster and oral presentation at ASCO-GI; Orlando, FL; January
24 In conclusion is the new standard of care in a palliative setting Improving OS by % And TTP by % Without worsening QoL Well tolerated Combinations are promising. Future of targeted therapies, in advanced HCC Head to head comparisons in st line / sorafenib Sunitinib, Brivanib, Bevacizumab + Erlotinib Phase III: sorafenib vs sorafenib + erlotinib Second line treatments (brivanib, retinoids, ) Phase II trials of combinations: Chemotherapy? M-TOR inhibitors,? Future of targeted therapies, in HCC: Combination with TACE Simultaneously «adjuvant» after Response Adjuvant to surgery / RFA Waiting period / OLT 24
25 BCLC staging and treatment strategy HCC Very early stage () Early stage (A) Intermediate stage (B) Advanced stage (C) Terminal stage (D) Single HCC Portal pressure/ bilirubin Increased Normal 3 nodules 3cm Associated diseases No Yes Extrahepatic disease No Yes Resection Liver transplantation PEI/RFA Chemoembolisation New agents Curative treatments? Randomised controlled trials Symptomatic +? treatment PEI = percutaneous ethanol injection RFA = radiofrequency ablation Llovet JM, et al. Lancet 23;362:97 7 Does sorafenib really work? Does sorafenib work? : PALLIATIVE TREATMENT Goal: to improve Overall survival Time to progression, Without impairing QoL Objective response rate = 2 3 % Then, goal of surveillance: To ensure that tumor is not progressing To find some signs of efficacy: 25
26 92 mm Aug 8th, 27 4th months of Brivanib June, 4th, 27 AFP = Nl Initiation of Brivanib Tt 8 mm EASL criteria in use in HCC particularly with biodrugs WHO RECIST EASL PR PR NC PR 26
27 EASL criteria in use in HCC particularly with biodrugs WHO EASL: RECIST VIABLE PR PR NC PR How to manage toxicities? Toxicities: not very severe, but => QoL We need: preventive measures patient s education in order: to avoid or limit toxicity to give full dose => full benefit How to manage toxicities? Diarrhea: avoid spicy food, milk, loperamide, then codeïne, eventually: 4 mg / d until resolution Asthenia, anorexia: alimentary support, check for anemia, hypo phosphosphatemia, 27
28 How to manage toxicities? Hand Foot Syndrome: Prevention Roomy shoes, moisturizing cream, Avoid hot temperatures Specific soles, Soft podiatry How to manage toxicities? Treat as soon as possible: Urea containing creams, corticoid creams Decrease dose => 4 mg/d to reevaluate on a weekly basis Back to 8 mg/d when major improvement (Gr -) If not: stop sorafenib for > 2 weeks When resolved: 4 mg every day or Every 2 days if it recurred. /// 28
29 Guidelines : hand foot skin reaction Occurrence Grade Grade 2 Grade 3 Institute supportive st measures immediately occurrence & continue sorafenib treatment Institute supportive measures & consider a decrease in sorafenib dose to 4 mg daily for 28 days If toxicity returns to If toxicity does not grade after dose OR return to grade reduction despite dose reduction Institute supportive measures & interrupt sorafenib treatment for a minimum of 7 days & until toxicity has resolved to grade All occurrences Increase sorafenib to full dose after 28 days Interrupt sorafenib treatment for a minimum of 7 days, until toxicity has resolved to grade When resuming treatment after dose interruption, resume sorafenib at reduced dose of 4 mg daily for 28 days If toxicity is maintained at grade at reduced dose When resuming treatment after dose interruption, resume sorafenib at reduced dose of 4 mg daily for 28 days If toxicity is maintained at grade at reduced dose Increase sorafenib to full dose after 28 days Increase sorafenib to full dose after 28 days 2 nd occurrence 3 rd occurrence 4 th occurrence As for st occurrence but, upon resuming sorafenib treatment, decrease dose to 4 mg daily indefinitely As for 2 nd occurrence Decision whether to discontinue sorafenib treatment should be made based on clinical judgement and patient preference As for st occurrence but decrease sorafenib dose to 4 mg daily indefinitely Decision whether to discontinue sorafenib treatment should be made based on clinical judgement and patient preference 29
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationSorafenib in HCC. Discussion points
Discussion points in Andrew X. Zhu, MD, PhD 214 CASL Meeting-Consensus, Controversies and Future Directions in -data from phase III trials ptimal Dosing Side effects and management strategies use in Child-Pugh
More informationCurrent Concepts in the Treatment of HCC
Falk Symposium 167 Current Concepts in the Treatment of HCC Peter R. Galle I. Medical Department Johannes Gutenberg-University Mainz Germany Liver cancer: sixth most common cancer worldwide Most common
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationΗπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία. Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018
Ηπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018 Advisory Board Disclosures Roche, Boeringer, Sanofi, Astra Zeneca,
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationTREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA
HCC treatment : A permanent challenge! TREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA Michel Ducreux, MD, PhD Paul Brousse University Hospital Gustave Roussy Institute Villejuif, FRANCE A low level of
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationNew Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC)
New Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC) Thomas W.T. Leung Associate Director and Honorary Consultant Comprehensive Oncology Centre Hong Kong Sanatorium and Hospital Hong
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationUPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA
UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HUSSEIN K. MOHAMED MD, FACS. Transplant and Hepato-biliary Surgery Largo Medical Center HCA DISCLOSURE I have no financial relationship(s) relevant to the
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationQUANDO LA TERAPIA MEDICA
IL NODULO EATICO dalla diagnosi.. alla terapia Sala Conferenze, Biblioteca "Rosanna Benzi" Genova Voltri 21 Settembre 2013 QUANDO LA TERAIA MEDICA Dott. Gianfranco ercario U.O.S. di Gastroenterologia OEI
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationWhen patients fail on molecular targeted therapy: what to do in 2013
When patients fail on molecular targeted therapy: what to do in 2013 For 3 rd APASAL HCC conference on 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationFirst-line therapy for unresectable HCC:
ESMO GI Cancer Preceptorship 15 November 2017 Singapore First-line therapy for unresectable HCC: an oncologist s viewpoint Chiun Hsu, MD, PhD G raduate I n stitute of Oncology, National Taiwan Univers
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationAddictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis
Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Gwang Hyeon Choi, Ju Hyun Shim*, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationManagement of side-effects of anti-angiogenetic inhibitors in treating HCC
Management of side-effects of anti-angiogenetic inhibitors in treating HCC Massimo Di Maio Clinical Trials Unit National Cancer Institute, Napoli dimaiomax@libero.it BCLC staging system and treatment strategy
More informationHEPATOCELLULAR CARCINOMA N. A.OTHIENO ABINYA
HEPATOCELLULAR CARCINOMA N. A.OTHIENO ABINYA - One of the most common solid organ tumours worldwide. - A public health problem in parts of Asia and subsaharan Africa, with incidence upto 50/100,000 population/year.
More informationHepatozelluläres Karzinom und Cholangiokarzinom was kommt nach Sorafenib? Stefan Kubicka
Hepatozelluläres Karzinom und Cholangiokarzinom was kommt nach Sorafenib? Stefan Kubicka SHARP 1 versus Asia-Pacific-Study 2 SHARP S:299/P:303 Asia-Pacific S:150/P:76 End point HR p-value HR p-value OS
More informationClinical Study Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study
International Scholarly Research Network ISRN Oncology Volume 2012, Article ID 420931, 5 pages doi:10.5402/2012/420931 Clinical Study Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationSorafenib for Advanced Hepatocellular Carcinoma
CED-SOS Advice Report 7 ARCHIVED 2012 Sorafenib for Advanced Hepatocellular Carcinoma J. Knox, R. Cosby, K. Chan, and M. Sherman A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer
More informationWelcome to Master Class for Oncologists. Miami, FL. December 19, The following relationships exist related to this presentation: Session 2
Session 2 Welcome to Master Class for Oncologists 8:15 AM 9:00 AM Miami, FL December 19, 2009 Alan P. Venook, MD Professor of Clinical Medicine University of California San Francisco Medical School Chief,
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationSystemic Cytotoxic Therapy in advanced HCC
Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationUnmet Needs in the Treatment of Advanced Hepatocellular Carcinoma
Unmet Needs in the Treatment of Advanced Hepatocellular Carcinoma Joong-Won Park Center for Liver Cancer National Cancer Center, Korea Advanced HCC Definition - An abtract concept, Not clear, No consensus
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationHow to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung
How to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung End points in research for solid cancers Overall survival (OS) The most ideal one, but requires long follow-up duration
More informationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Published online: March 9, 2017 Editorial A New Era of Systemic Therapy for Hepatocellular Carcinoma with Prof. M. Kudo Editor Liver Cancer Introduction The SHARP study in 2007 [1] and the Asia Pacific
More informationThe Management of Advanced Stage Hepatocellular Carcinoma
The Management of Advanced Stage Hepatocellular Carcinoma Pierce K.H Chow MD PhD Professor, Duke-NUS Graduate Medical School Singapore Senior Consultant Surgeon, National Cancer Center Singapore Senior
More informationMolecular Biology of Hepatocellular Carcinoma and Targeted Therapies
Molecular Biology of Hepatocellular Carcinoma and Targeted Therapies First International Course on Translational Hepatology: Focus on HCV Disease March 9-11, 2011 Melanie B. Thomas, M.D. Associate Director
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationSi Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong Jun Song, 1,4 Woo Jin Chung, 1,5
Comparison of efficacy between hepatic arterial infusion chemotherapy and sorafenib in advanced hepatocellular carcinoma with portal vein tumor thrombosis 1,2,3 Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong
More informationAn Update on Hepatocellular Carcinoma. Ed Gane NZ Liver Transplant Unit
An Update on Hepatocellular Carcinoma Ed Gane NZ Liver Transplant Unit Hepatocellular Carcinoma has a High Burden of Disease APSCVIR March 2018 Lung Liver Colon/Rectal Stomach Breast Cervix Uteri Esophagus
More informationOptimal management of HCC: in Asia
Optimal management of HCC: in Asia Kwang-Hyub Han, MD Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea Newly diagnosed HCC : > 70% occur
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationSorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Journal of the Egyptian National Cancer Institute (2014) 26, 9 13 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com Original article Sorafenib for
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationCurrent Standards of Care of Hepatocellular Carcinoma? Prof. Mohsen Mokhtar M.D Cairo Univ.
Current Standards of Care of Hepatocellular Carcinoma? Prof. Mohsen Mokhtar M.D Cairo Univ. Disclosures Honoraria Received : Amgen, Astra Zeneca, Bohrengier, Hikma,Hospira, GSK, Lilly, Merck, MSD, Novartis,
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology, & Nutrition University of Louisville & Louisville VAMC 2010 Magnitude of the Problem 95% of
More informationManagement of advanced Hepatocellular carcinoma
Management of advanced Hepatocellular carcinoma V Di Martino* Acknowledgements to T Thevenot *Advisory board/lectures/travel facilities: Case report (1) Mr T. Philippe 55 yrs old Past IV drug user (1985)
More informationTRANSPARENCY COMMITTEE OPINION. 5 March 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 March 2008 NEXAVAR 200 mg, film-coated tablet B/112 (CIP: 376 137-2) Applicant: BAYER SANTE sorafenib List I Medicinal
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Ghassan K. Abou-Alfa Memorial Sloan Kettering Cancer Center Great Debates & Updates in GI Malignancies New York, NY March 28, 2015 Epidemiology Scoring and staging Agenda Curative
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationONCOLOGY LETTERS 5: , JUAN DU, XIAOPING QIAN and BAORUI LIU. Received July 15, 2012; Accepted October 9, DOI: /ol.2012.
ONCOLOGY LETTERS 5: 381-385, 2013 Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of
More informationIl Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali
Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationHepatocellular carcinoma: from guidelines to individualized treatment
AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal
More informationAntiviral Therapy and Liver Cancer
Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationTherapeutic Response Assessment and Endpoints in HCC
APASL HCC Conference, 2013 Cebu Therapeutic Response Assessment and Endpoints in HCC Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Surgery Chief of Hepatobiliary and Pancreatic Surgery The University
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationin Hepatocellular Carcinoma
in Hepatocellular Carcinoma The following summarises the key data supporting the use of SIR-Spheres Y-90 resin microspheres in the treatment of primary liver cancer due to hepatocellular carcinoma (HCC):
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationHepatocellular Carcinoma: Transplantation, Resection or Ablation?
Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationLiver and Biliary Tract Cancers Critical Review
Liver and Biliary Tract Cancers Critical Review Lorenza Rimassa Oncologia Medica e Ematologia Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Critical review Oral presentations Melero
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationUPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA*
UPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA* Dr. Catherine Frenette Medical Director of Liver Transplantation, Scripps Green Hospital, La Jolla, CA, USA May 2018
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationBenefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
Regulatory Issues: FDA Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib LORRAINE PELOSOF, STEVEN LEMERY, SANDRA
More informationLiver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine
Liver Cancer Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Primary Liver Cancer Hepatocellular carcinoma (HCC) : > 80% Derived
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationPancreatic NeuroEndocrine Tumors. Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium
Pancreatic NeuroEndocrine Tumors Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Epidemiology Overall incidence 1.8 to 2.6 SEER, Europe Peak in 5 th and 6 th decade Incidence
More information